Lataa...
PRDM1 is required for Mantle Cell Lymphoma response to Bortezomib
Mantle cell lymphoma (MCL) is an aggressive form of B cell lymphoma with a poor disease- free survival rate. The proteasome inhibitor, Bortezomib, is approved for treatment of relapsed and refractory MCL and has efficacy in about 30% of patients. However, the precise mechanism of action of Bortezomi...
Tallennettuna:
| Päätekijät: | , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2891394/ https://ncbi.nlm.nih.gov/pubmed/20530581 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-10-0131 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|